ESMO FAMILY SITES
ESMO » CAREER & GRANTS » FELLOWSHIP CORNER » FELLOWSHIP OFFERS » ALUMNI AND REPORTS » FELLOWS REPORTS
Fellows reports
2009-2010
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2009-2010 | Balazs Dome | National Koranyi Institute of Pulmonology, Piheno utca 1 - 1525 Budapest, Hungary | Department of Surgery, Medial University of Vienna, Wahringer Gurtel 18-20, Vienna A-1090 |
Role of lymphatic/vascular endothelial progenitor cells in human non-small cell lung cancer |
Roche |
| 2009-2010 | Laurent Quero | Saint Louis University Hospital - 1 Avenue Claude Vellefaux 75010 Paris . France |
University Hospital Maastricht - Dpt of Radiation Oncology (MAASRO) dr. Tanslanna, 12 - 6229 Et Maastricht- The Netherlands | CA9: A target for imaging and treatment in prostate cancer |
Pfizer Oncology |
| 2009-2010 | Yoko Yanagisawa | Department of Surgery Shinshu University Shool of Medicine 3-1-1 Asahi, 390-8621 Matsumoto Japan |
Department Clinical Pharmacology Old Road Campus Research Building Old Road Campus off Roosebelt Drive Oxford UK | Molecular Markers of Response to colerectal Cancer Therapy |
Novartis |
| 2009-2010 | Giorgi Dzagnidze | National Cancer Center of Georgia, 0177 Lisi Lake N1, 0177 Tbilisi Georgia |
School of Clinical Sciences, Professorial Unit of Surgery, City Hospital Hucknall Road, Nottingham, NG5 1PB | The Role of Autoimmunity in Breast Cancer Diagnosis |
MSD |
| 2009-2010 | Eleni Karapanagiotou | Oncology Unit, 3rd Department of Internal Medicine Athens Medical School, Sotiria General Hospital - 115-27 Athens Greece | The Royal Marsden Hospital & The Institute of Cancer Research, Fulham Road, London SW3 6JJ |
Evaluation of Oncolytic Virotherapies in Combination with Cytotoxic Chemotherapy and Immunomodulatory Therapy in Patients with Advanced Cancers |
Roche |
| 2009-2010 | Giannis Mountzios | 251 General Hospital Airforce Hospital - Katsimpiti 4A, Xolargos - 15561 Athens Greece |
University Hospital Alexandra V Sofias and Lourou, Athens Greece |
Maricers of bone remodeling as predictors of skeletal morbidity and clinical outcome in patients with solid tumours metastatic to the skeleton receiving the biphosphonate zoledronic acid | Roche |
2008-2009
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2008-2009 | Alimonti Andrea | Beth Israel Deaconess Medical Center - Harvard Medical School 476 Massachusetts avenue apt. 1 02118 Boston USA | San Pietro Fatebenefratelli Research Institute Via Cassia 600 Rome Italy | A small molecules screening for the identification of enhancers of Pten-loss Induced Cellular Senescence (PICS) | Amgen |
| 2008-2009 | Chigrinova Ekaterina | NN Blokhin Cancer Research Center Russian Academy of Medical Sciences Kashirsroye Sh.,24, 115478 Moscow Russia | Oncology Institute of Southern Switzerland 6500 Bellinzona |
Identification of the Genomic Lesions underlying Richter’s Syndrome | Roche |
| 2008-2009 | Dufresne Armelle | Department of Medical Oncology Pavillon E - Hospital Edouard herriot, 5 place d'Arsonval, 69437 Lyon Cedex 03 | Team 5 - Equipe Cytokine et Cancer - of the INSERM U590 Unit - Centre Leon Berard - Lyon, France | Identification of predictive factors for response to targeted therapies and biological criteria of aggressiveness in two models of connective tissue tumor with locoregional spread: aggressive fibromatosis/desmoids tumor (AF/DT) and pigmented villo-nodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT) | Merk Serono |
| 2008-2009 | Ferraldeschi Roberta | Policlinico Umerto I, University of Rome "Sapienza" Viale Regina Elena 324, 00161 Rome Italy | Christie Hospital NHS foundation Trust, Wilmslow Road, M 20 4Bx United Kingdom | Pharmacogenetics of aromatase inhibitors a companion study to the ‘Arimidex’ Tamoxifen, Alone or in combination (ATAC) trial | ESMO |
| 2008-2009 | Golfinopoulos Vassilios | DPT. of Medical Oncology Ioannina University Hospital, Ioannina, Greece | Institut Jules Bordet - Bruxelles | Evaluation of the role of PIK3CA mutations in PI3K/AKT pathway activation in primary and secondary resistance to Lapatinib in gastric cancer | ESMO |
| 2008-2009 | Gojis Ondrej | Department of General Surgery, Department of Pathology, 3rd Medical Faculty Charles University in Prague Ruska 87, Praha 10 110 00 Czech Rep. |
Department of Cancer Medicine, Imperial College London Du Cane Road London W12 0NN, UK |
The Role of AIB1 in Regulating Estrogen Receptor Gene Expression in Human Breast Cancer | GSK |
| 2008-2009 | Hess Viviane | University Hospital Basel, Division of Onocology Petersgraben 4 4031 Basel Switzerland | Royal Marsden Hospital Fulham road, London SW5 6JJ - UK | Prognostic factors for patients with central nervous system metastases from renal cell carcinoma | Novartis |
| 2008-2009 | Massard Christophe | Institut Gustave Roussy 39 rue Camille Desmoulins 94800 Villejuif, France | Royal Marsden Hospital UK | To evaluate the utility of the molecular characterization of CTCs in the treatment of castration resistant prostate cancer patients with moleculary targeted drugs. | Amgen |
| 2008-2009 | Morgillo Floriana | Oncologia Medica, Seconda Università Studi di Napoli, Dipartimento "Magrassi-Lanzara", Edificio 3, II Policlinico, Via Sergio Pansini 5, 80131 Naples, Italy | Oncologia Medica, Seconda Università Studi di Napoli, Dipartimento "Magrassi-Lanzara", Edificio 3, II Policlinico, Via Sergio Pansini 5, 80131 Naples, Italy | Mechanisms of acquired resistance to anti-growth factor receptor agents | Roche |
| 2008-2009 | Saghatchian Mahasti | Institut Gustave Roussy 39 rue Camille Desmoulins 94800 Villejuif, France | The Netherland Cancer Institute - The Netherlands | Development of molecular profiling of breast cancers | ESMO |
2007-2008
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2007-2008 | Celebic Aleksandar | Institute of Oncology and Radiology of Serbia. Belgrade, Serbia |
Institut Gustave Roussy, Villejuif France |
Search for a Q-RT-PCR gene expression profile of benign breast tissue associated with high breast cancer risk | Amgen |
| 2007-2008 | Cresti Nicola | Medical Oncology Division, St. Chiara University Hospital, Pisa, Italy |
Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle, UK |
Pharmacogenetic study of FcyRlllA and HER2 genes in relation to treatment of breast cancer | Amgen |
| 2007-2008 | Loi Sherene | Department of Medical Oncology & Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia |
Jules Bordet Institute, Brussels, Belgium |
Understanding the molecular heterogeneity of response and resistance to anti-HER2/ErbB2 agents in breast cancer | Novartis |
| 2007-2008 | Markman Ben | Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain |
Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain |
Effects of Pl3K Pathway Inhibition and Biomarker Development | Wyeth Pharmaceuticals |
| 2007-2008 | Opitz Isabelle | Division of Thoracic Surgery, University Hospital Zurich Zurich, Switzerland |
Clinic and Policlinic for Oncology, University Hospital Zurich Zurich, Switzerland |
Intrapleural therapy after surgery for malignant pleural mesothelioma | Bayer Oncology |
| 2007-2008 | Zoubir Mustapha | Centre Hospitalo-Universitaire d'Oran, Oran, Algerie |
Institut Gustave Roussy, Villejuif France |
Novel subset of regulatory immune cell: characterization of inhibitory NKalb | GE Healthcare |
2006-2007
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2006-2007 | Atzori Francesco | University of Cagliari, Cagliari Italy |
Vall d'Hebron University Hospital, Barcelona, Spain | A phase III randomized, controlled trial of myocet, trastuzumab and paclitaxel versus trastuzumab and paclitaxel for first line therapy of metastitic breast cancer | Amgen |
| 2006 | Jan Wierecky | Dept. of Hematology-Oncology University Medicine Center Hamburg Eppendorf, Germany | Cantonal Hospital St. Gallen, St. Gallen, Switzerland | Research project. Participation in the outpatient E-MOSAIC trial with an amended inpatient version. | |
| 2006-2007 | Koychev Daniel | Medical University of Plovdiv, Plovdiv, Bulgaria |
Charité Campus Benjamin Franklin Berlin, Germany | The role of Pax genes for regulation of the Wilm's tumor gene 1 (WT1) in carcicoma cells and tumor cell proliferation | Amgen |
| 2006-2007 | Lyros Orestis | University of Athens Medical School, Athens Greece |
Mainz University Clinic, Mainz Germany |
Molecular markers of tyrosine kinase signaling receptor pathways for clinical prognosis and prediction under TKI therapy in human gastrointestinal in vivo and in vitro | AstraZeneca |
| 2006-2007 | Olmos Hidalgo David | Hospital Clinico Universitario de Malaga, Malaga, Spain |
Royal Marsden Hospital, Sutton, UK |
Utilizing circulating tumor cells to identify molecular targets and to optimize drug selection and treatment in patients with hormone refractory prostate cancer | Bayer Oncology |
| 2006-2007 | Ruiz Soto Rodrigo | Instituto Nacional de Cancerologia Mexico City, Mexico |
Institut Gustave Roussy, Villejuif, France |
Search for predictive biomarkers of response to induction chemotherapy API-AI (doxorubicin, ifosfamide and cisplatine) in patients with locally advanced soft tissue sarcoma | Wyeth Pharmaceuticals |
| 2006 | Pusceddu Valeria | Policlinico Universitario, 09042 Monserrato, CA, Italy | Velindre Cancer Center, Cardiff, United Kingdom | Palliative Care: Observational Project for Pain Control | |
| 2006-2007 | Wermann Hendrik | Universitätsklinikum Hamburg-Eppendorf Hamburg, Germany |
Erasmus Medical Center Rotterdam, The Netherlands |
The role of microsatellite instability and BRAF mutations in chemotherapy resistance of germ cells tumors | Novartis |
2005-2006
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2005-2006 | Aydin Semra | University |
University of Turin |
CD 38 signaling in B-cell chronic lymphocytic leukaemia (B-CLL) | AstraZeneca |
| 2005-2006 | Bradic Maja | Institute of Oncology Sremsak Kamenica Sremska Kamenica, Serbia and Montenegro |
Cancer Center Karolinska Stockholm, Sweden |
Development of PDGF receptors as clinical cancer drug targets | Amgen
|
| 2005 | Conforti Rosa | Ospedale Bellaria |
Institut Gustave Roussy Villejuf Cedex, France |
Predictive factors for the benefit of adjuvant chemotherapy in breast cancer patients: A biomarker project | ESMO |
| 2005-2006 | Mountzios Ioannis | 251 Airforce General Hospital |
Institute Gustave Roussy Villeiuf Cedex, France |
Study of interactive activation of melecolar Signalling pathways in non-small cell lung cancer (NSCLC) in relation to histological and clinical features | ESMO |
| 2005-2006 | Palma Marzia | Medical Oncology, La Sapienza University, Rome, Italy |
Cancer Centre Karolinska, Radiumhemmet Stockholm, Serden |
Leukemia specific T cells in chronic lymphocitic leukaemia and the development of a leukaemia specific vaccination approach | Ortho Biotech |
2004-2005
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2004-2005 | Akimov Mikhail | N.N. Petrov Research Inst. of Oncology St. Petersburg, Russia |
Krankenhaus Nordwest Frankfurt, Germany |
Expression and Immunogenicity of the Tumor Associated Antigens in Lung Cancer Patients | Merck |
| 2004-2005 | Godal Robert | National Cancer Institute |
Charite Campus |
Regulation of WT1 expression in human solid tumors and presentation to the immune system | Amgen |
| 2004-2005 | Martinelli Erika | University of Naples |
Vall d'Hebron University Hospital |
To investigate the effects of the mTOR inhibitor everolimus (RAD001) in patients with advanced solid tumours | Ortho Biotech |
| 2004-2005 | Neciosup Delgado Silvia | Instituto de Enfermedades Neoplasicas |
Hospital Universitario 12 de Octubre Madrid, Spain |
Phase I clinical, pharmacokinetic and biological trial with escalating doses of the PPARg ligand Pioglitazone in patients with advanced solid tumors | AstraZeneca |
| 2004-2005 | Palma Marzia | Medical Oncology, |
Cancer Centre Karolinska Radiumhemmet Dept of Oncology Stockholm, Sweden |
Leukemia specific T cells in chronic lymphocitic leukemia and the development of a leukemia specific vaccination approach | ESMO |
2003-2004
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2003-2004 | Besse Benjamin | Institut Gustave Roussy Dept of Medicine Villejuif, France |
Institut Català d'Oncologia Medical Oncology Dept Badalona, Spain |
Research on genetic assessment of chemotherapy response | ESMO |
| 2003-2004 | Godal Robert | National Cancer Inst. Dept. Internal Medicine Bratislava, Slovak Rep. |
FU Berlin Medizinische Klinik III Berlin, Germany |
Regulation of WT1 expression in human solid tumors and presentation to the immune system | ESMO |
| 2003-2004 | Joerger Markus | Kantonsspital St. Gallen Dept Innere Medizin St. Gallen Switzerland |
The Netherlands Cancer Inst. A. van Leeuwenhoek Hospital Div of Medicine Amsterdam, Netherlands |
Pharmacogenotyping and –phenotyping in cancer patients to explore associations with anticancer drug pharmacokinetics and toxicity | ESMO |
| 2003-2004 | Wannesson De Nicola Luciano | Fundaleu Buenos Aires, Argentina |
Oncology Institute of Southern Switzerland Ospedale S Giovanni Bellinzona, Switzerland |
Development of analogs in solid tumors an oral camptothecin in non small cell lung cancer NSCLC | ESMO |
| 2003-2004 | Vischioni Barbara | Ospedale Luigi Sacco Milan, Italy |
Free University Hospital Dept of Med Oncology 1117 De Boelelaan Amsterdam, Netherlands |
Nuclear-cytoplasmic localization of IAPs as novel marker for tumor progression | ESMO |
2002-2003
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2002-2003 | Bellova Veronika | NCI Dept of Internal Medicine Bratislava, Slovak Rep. |
Universitätsklinikum Köln Klinik I für Innere Medizin Köln, Germany |
1. APVG – a regimen for first line treatment of elderly patients with Hodgkin's disease 2. The development of new immunotherapeutic approaches for patients with Hodgkin's disease |
ESMO |
| 2002-2003 | Galani Eleni | Alexandra Hospital Dept of Clinical Therapeutics Athens, Greece |
Guy's & St. Thomas Hospital St. Thomas Street London, United Kingdom |
Detection of specific T-cells in the peripheral blood and in the bone marrow of patients with early breast cancer recognizing epitopes from Tumor Antigens | ESMO |
| 2002-2003 | Michalaki Vasiliki | University of Athens Oncology Unit 3rd Dept of Medicine Athens, Greece |
Royal Marsden Hospital NHS Trust London, United Kingdom |
Novel gene therapy approaches (prodrug enzyme therapy) in patients with locally advanced and/or relapsed head and neck cancer | ESMO |
| 2002-2003 | Teterin Alexei | Novosibirsk Regional Diagnostic Centre Novosibirsk, Russian Federation |
University Clinic of Vienna Dept of Oncology Vienna, Austria |
Isolation of tumor DNA/RNA from the sera of patients with prostate carcinoma | ESMO |
| 2002-2003 | Vera Karina | Hospital Britanico Medical Oncology Buenos Aires, Argentina |
Institut Gustave Roussy Medical Phase I Unit Villejuif, France |
Phase I ascending dose study of intravenous ES-285 in patients with advanced malignant solid tumors | ESMO |
2001-2003
Period |
Name |
Home Institute |
Host Institute |
Project Topic |
Sponsored by |
| 2001-2003 | Bologna Fabrina | University of La Plata Faculty of Medicine La Plata, Argentina |
Istituto Nazionale dei Tumori Milan, Italy |
Correlation between tumor markers and response to systemic doxorubicin/paclitaxel neoadjuvant chemotherapy in patients with locally advanced breast cancer | ESMO |
2001-2003 |
Kulimova Emma |
National Hematology Research Centre Moscow, Russian Fed. | Medizinische Klinik &Poliklinik Innere Medizin Münster, Germany |
Tissue inhibitor of metallo-proteinases 1 (TIMP-1) is an autocrine/paracrine survival factor with additional immune-regulatory functions expressed by Hodgkin-Reed/Sternberg (H‑R/S) cells |
ESMO |
BACK TO TOP
PRINT THIS PAGE